However, compared to PPP [3-7] treatment with anti-IGF-1R antibodies exhibited relatively weak anti-tumor effects in preclinical models [8, 9], and have yielded disappointing clinical data [1, 10]. The gene discussed is IGF1R; the disease is neoplasm.